A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells - PubMed (original) (raw)
A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells
Siew Wee Chan et al. Cancer Res. 2008.
Abstract
TAZ (WWTR1), identified as a 14-3-3 binding protein with a PDZ binding motif, modulates mesenchymal stem cell differentiation. We now show that TAZ plays a critical role in the migration, invasion, and tumorigenesis of breast cancer cells. TAZ is conspicuously expressed in human breast cancer cell lines in which its expression levels generally correlate with the invasiveness of cancer cells. Overexpression of TAZ in low-expressing MCF10A cells causes morphologic changes characteristic of cell transformation and promotes cell migration and invasion. Conversely, RNA interference-mediated knockdown of TAZ expression in MCF7 and Hs578T cells reduces cell migration and invasion. TAZ knockdown in MCF7 cells also retards anchorage-independent growth in soft agar and tumorigenesis in nude mice. Significantly, TAZ is overexpressed in approximately 20% of breast cancer samples. These results indicate that TAZ plays a role in the migration, invasion, and tumorigenesis of breast cancer cells and thus presents a novel target for the detection and treatment of breast cancer.
Similar articles
- ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
Liu CY, Yu T, Huang Y, Cui L, Hong W. Liu CY, et al. J Biol Chem. 2017 Jun 2;292(22):9420-9430. doi: 10.1074/jbc.M117.783787. Epub 2017 Apr 13. J Biol Chem. 2017. PMID: 28408625 Free PMC article. - Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, Peng SX, Chen LW, Li YW. Cao D, et al. Biomed Pharmacother. 2020 Sep;129:110462. doi: 10.1016/j.biopha.2020.110462. Epub 2020 Jul 6. Biomed Pharmacother. 2020. PMID: 32768952 - TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME, Lutz T, Bissinger M, Sticht C, Knaub M, Gretz N, Schirmacher P, Breuhahn K. Weiler SME, et al. Cancer Lett. 2020 Mar 31;473:164-175. doi: 10.1016/j.canlet.2019.12.044. Epub 2020 Jan 3. Cancer Lett. 2020. PMID: 31904487 - MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells.
Liu CY, Chan SW, Guo F, Toloczko A, Cui L, Hong W. Liu CY, et al. Oncotarget. 2016 Mar 22;7(12):13706-16. doi: 10.18632/oncotarget.7333. Oncotarget. 2016. PMID: 26885614 Free PMC article. - Regulation of TAZ in cancer.
Zhou X, Lei QY. Zhou X, et al. Protein Cell. 2016 Aug;7(8):548-61. doi: 10.1007/s13238-016-0288-z. Epub 2016 Jul 14. Protein Cell. 2016. PMID: 27412635 Free PMC article. Review.
Cited by
- α-Arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis.
Arakaki AKS, Pan WA, Wedegaertner H, Roca-Mercado I, Chinn L, Gujral TS, Trejo J. Arakaki AKS, et al. J Cell Sci. 2021 Apr 15;134(8):jcs254888. doi: 10.1242/jcs.254888. Epub 2021 Apr 22. J Cell Sci. 2021. PMID: 33722977 Free PMC article. - SnoN Antagonizes the Hippo Kinase Complex to Promote TAZ Signaling during Breast Carcinogenesis.
Zhu Q, Le Scolan E, Jahchan N, Ji X, Xu A, Luo K. Zhu Q, et al. Dev Cell. 2016 Jun 6;37(5):399-412. doi: 10.1016/j.devcel.2016.05.002. Epub 2016 May 26. Dev Cell. 2016. PMID: 27237790 Free PMC article. - YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A. Hergovich A. Breast Cancer Res. 2012 Dec 5;14(6):326. doi: 10.1186/bcr3349. Breast Cancer Res. 2012. PMID: 23216692 Free PMC article. - Poly(rC)-Binding Protein 2 Regulates Hippo Signaling To Control Growth in Breast Epithelial Cells.
Li F, Bullough KZ, Vashisht AA, Wohlschlegel JA, Philpott CC. Li F, et al. Mol Cell Biol. 2016 Jul 29;36(16):2121-31. doi: 10.1128/MCB.00104-16. Print 2016 Aug 15. Mol Cell Biol. 2016. PMID: 27215387 Free PMC article. - A comprehensive evaluation of Hippo pathway silencing in sarcomas.
Merritt NM, Fullenkamp CA, Hall SL, Qian Q, Desai C, Thomason J, Lambertz AM, Dupuy AJ, Darbro B, Tanas MR. Merritt NM, et al. Oncotarget. 2018 Aug 3;9(60):31620-31636. doi: 10.18632/oncotarget.25824. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical